Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from EMERGENT

Emergent no-code review

Efficient no-code solution with its own IDE for easier development.

Kuku FM readies public market debut; SoftBank books Lenskart gains

Kuku FM readies public market debut; SoftBank books Lenskart gains

Kuku FM's parent has taken the first step towards a stock market listing. This and more in today's ETtech Top 5.

The Economic Times

Together Fund’s Manav Garg joins portfolio firm Emergent as executive chairman

Together Fund’s Manav Garg joins portfolio firm Emergent as executive chairman

Announcing the move in a LinkedIn post on Thursday, Garg stated that he will continue supporting founders and portfolio companies at Together Fund alongside his new responsibilities at Emergent.

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Peak XV, Activate in talks to invest in Silicon Valley AI dictation startup Wispr Flow

Founded by Stanford graduates Tanay Kothari and Sahaj Garg, Wispr Flow develops a voice dictation tool that allows users to speak into apps and workflows instead of typing. The latest funding is likely to nearly triple its valuation to $2 billion, per people in the know.

The Economic Times

Nvidia may lead AI startup Simplismart’s $20 million fundraise at $100 million valuation

Chipmaking giant Nvidia is reportedly in advanced talks to lead a $20 million funding round for Simplismart, valuing the AI infrastructure startup at approximately $100 million. Earlier this year, Simplismart said its AI inference platform would be made available on Nvidia infrastructure as the startup expanded its enterprise AI offerings.

The Economic Times

SAB Biotherapeutics Q1 Earnings Call Highlights

SAB Biotherapeutics (NASDAQ:SABS) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider first-quarter loss alongside higher research and development spending. Chief Executive Officer Sa

From three-person startups hitting $500K ARR to Meta's CEO avatar project, AI agents are reshaping what a "team" looks like.

From three-person startups hitting $500K ARR to Meta's CEO avatar project, AI agents are reshaping what a "team" looks like.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts

3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts

Discover three low P/E small-cap stocks with bullish analyst sentiment and growth potential in a lower interest rate environment

Big Rallies Brewing? 3 Analyst Favorites to Watch Closely

Big Rallies Brewing? 3 Analyst Favorites to Watch Closely

Despite share price pops after earnings, SKYT, EBS, and BLZE may still have room to rally further, as each firm has garnered strong analyst support.

3 Groups File Competing Claims For Sam Bankman-Fried's $11B Forfeited Assets

3 Groups File Competing Claims For Sam Bankman-Fried's $11B Forfeited Assets

Sam Bankman-Fried was ordered to forfeit $11 billion in assets after he was found guilty of fraud and other related charges late last year, and now three separate groups are claiming all or some of the assets linked to the collapse of the FTX crypto empire.

International Business Times

Editorial: A potential lifesaver

There is hope in the news that the leading version of naloxone, the No. 1 drug used to reverse opioid overdoses, will soon be available without a prescription. Making it easier to obtain the life-saving drug should save lives, but the devil, as they say, may be in the details.

Tribune News Service

Robinhood to buy back Sam Bankman-Fried's stake in brokerage

Robinhood to buy back Sam Bankman-Fried's stake in brokerage

The decision follows a months-long fight over who owns the 7.6% stake in Robinhood after FTX declared bankruptcy.

Sam Bankman-Fried's lawyers just filed a claim to keep his $450 million in Robinhood shares, arguing he needs them for legal fees

Sam Bankman-Fried's lawyers just filed a claim to keep his $450 million in Robinhood shares, arguing he needs them for legal fees

The disgraced crypto founder, once worth $26.5 billion, said he only has $100,000 in his bank account.

Countries band together to keep forest promise

Countries band together to keep forest promise

More than 25 countries at the COP27 climate talks on Monday launched a group they said would ensure they hold each other accountable for a pledge to end deforestation by 2030 and announced billions of dollars to finance their efforts.

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

At concert outside Baltimore plant, musicians protest Maryland pharmaceutical company’s Narcan prices

BALTIMORE — Joined by harm-reduction advocates, local musicians performed outside a Baltimore drug manufacturing facility Wednesday afternoon to protest the price of the overdose-reversing drug Narcan sold by pharmaceutical company Emergent BioSolutions.

Tribune News Service

More than a half billion doses of COVID vaccine made in Baltimore dumped, congressional panel finds

BALTIMORE — The tally of wasted COVID-19 vaccine continues to climb at the troubled Emergent BioSolutions plant in East Baltimore and now exceeds a half billion doses, according to findings a congressional panel released Thursday on the manufacturer once central to the U.S. coronavirus pandemic response.

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug

Here's a roundup of top developments in the biotech space over the last 24 hours:

Morning Brief: Top Financial Stories Dominating on Tuesday, June 7

Get all your
news in one place.

100's of premium titles.
One news app.

J&J Serves Notice To Emergent For Terminating COVID-19 Shot Contract As Two Accuse Each Other Of Breach Of Agreement

Johnson & Johnson (NYSE: JNJ) has made another move towards severing its Covid-19 vaccine manufacturing ties with contract manufacturer Emergent Biosolutions, Inc. (NYSE: EBS).

Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract

Emergent BioSolutions Inc (NYSE: EBS) said Johnson & Johnson (NYSE: JNJ) had breached an agreement by failing to buy the company's minimum quantity of COVID-19 vaccines.

Chimerix Shares Plummet After Divesting Its Only Marketed Product For Over $300M

Emergent BioSolutions Inc (NYSE:EBS) has agreed to acquire Chimerix Inc's (NASDAQ:CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups for smallpox. "It exemplifies our thoughtful M&A strategy as part of our 2024 growth plan and positions us better to deliver value for our shareholders," said Robert Kramer, president…

Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco

According to a recent report from the US House select subcommittee on the coronavirus crisis, Emergent Biosolutions Inc (NYSE:EBS) might have destroyed nearly 400 million doses of COVID-19 vaccines after failing to meet quality standards. Initially, 75 million - 85 million doses of drug substance were said to be destroyed after contamination. "Despite major…

Tribune News Service

400 million COVID-19 vaccine doses dumped by Baltimore plant, congressional report finds

BALTIMORE — The Maryland-based vaccine maker Emergent BioSolutions was forced to destroy nearly 400 million doses of COVID-19 vaccine because of potential contamination at its East Baltimore plant, far more than previously known.

Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial

According to an SEC filing, Karuna Therapeutics Inc (NASDAQ:KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial evaluating KarXT in schizophrenia. The Company had expected topline data from the EMERGENT-3 trial in 2H of 2022. At this time, the escalating conflict in Ukraine…

1

People

200,974 stories

Mark Zuckerberg

Sam Bankman-Fried

Carolyn Maloney

Carolyn B Maloney

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Justice Department

Wall Street Journal

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

395,136 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play